“A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C] TAK-831 in Male Healthy Participants”
The purpose of this study is to determine ABA of TAK-831 following a single microdose intravenous administration of 50 microgram (mcg) (approximately 1 microcurie [mcCi]) [14C] TAK-831 and a single oral administration of 500 milligram (mg) TAK-831 tablets in Period 1, and to assess the mass balance, characterize the PK of TAK-831 in plasma and urine, and total radioactivity concentration equivalents in plasma and whole blood following a single oral suspension dose of 500 mg (approximately 100 mcCi) [14C]TAK-831 in Period 2.
Drug - TAK-831 Oral Tablet
Drug - [14C]TAK-831 Intravenous Infusion
[14C]TAK-831 intravenous infusion.
Drug - [14C]TAK-831 Oral Suspension
[14C]TAK-831 oral suspension.
A Phase 1 Study to Assess Absolute Bioavailability of TAK-831 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Subjects